415-389-4670655 Redwood Highway #395, Mill Valley, California 94941
TwitterFacebookLinkedin
Liviakis Financial Communications Inc.Liviakis Financial Communications Inc.
Liviakis Financial Communications Inc.
Comprehensive Investor Relations Services in partnership with growth companies
  • HOME
  • ABOUT LIVIAKIS
  • SERVICES
  • CORPORATE PORTFOLIO
  • NEWS
    • COMPANY NEWS
    • OUR BLOG
  • CONTACT
Menu back  

Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

May 2, 2019

GlobeNewswire•May 2, 2019

CHICAGO, May 02, 2019 (GLOBE NEWSWIRE) — Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA.

Under the terms of the agreement, Meroven LLC will be responsible for conducting all regulatory activities to obtain marketing authorizations for Spee-D as well as marketing and distribution. CURE will be responsible for the manufacture of Spee-D and its supply to Meroven at a predetermined transfer price.

“This agreement will broaden the reach of our high dose Vitamin D3 CUREfilm™ across the USA,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical. “As we continue to grow our product pipeline, we look forward to continued and expanded opportunities to work with Meroven.”

“CURE Pharmaceutical has cultivated an exceptional reputation in terms of their efficiency and purity of its internal formulation and manufacturing processes,” said Mohammed Alaa, Director of Meroven LLC. “We look forward to a long and fruitful relationship with CURE and anticipate its potential expansion.”

For more information, please visit Booth No. 852 at the CPhI North America Conference May 1-2, 2019 where both Meroven LLC and CURE Pharmaceutical representatives will be available.

About Spee-D® (vitamin D3) oral thin film
Spee-D is an oral thin film that delivers vitamin D3 formulated with CURE’s proprietary CUREfilm™ technology that ensures high potency and stability. Vitamin D is a fat-soluble vitamin that is naturally present in very few foods, added to others, and available as a dietary supplement. It is also produced endogenously when ultraviolet rays from sunlight strike the skin and trigger vitamin D synthesis. Vitamin D promotes calcium absorption and is essential for bone growth. Vitamin D also prevents rickets in children and osteomalacia in adults. Together with calcium, vitamin D also helps protect older adults from osteoporosis.

About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.

About Meroven LLC
Meroven LLC is a Florida-based Pharmaceutical company that manufactures and trades in medical, pharmaceutical, OTC and other healthcare products. Meroven’s scope of business includes manufacturing pharmaceutical and healthcare products and trading in medical devices, durable medical goods and consumables.
Meroven LLC has established strategic international partnerships with other leading companies in healthcare to support its vision. These partnerships span from USA, Canada, and the EU. Meroven offers its clients quality generic medicines that fill a niche, gap and/or offer innovative technologies for delivery.

Forward-Looking Information
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, the efficacy of Spee-D® and its use. On February 28, 2017, and ending on August 28, 2020, Liviakis Financial Communications, Inc. (LFC) was retained by CURE Pharmaceutical Holding Corp. (CURR) in various consulting capacities including strategic management planning, investor relations and other business development responsibilities. LFC was compensated 1,000,000 restricted common stock under rule 144. Officers and employees of LFC will buy or sell shares in CURE Pharmaceutical Holding Corp. prior, during or after this release. LFC advises CURE Pharmaceutical Holding Corp. but does not provide investment advice. LFC is not a registered investment advisor or broker-dealer. All material provided regarding CURE Pharmaceuticals Holding Corp. including, but not limited to its history, corporate status, and other developments was prepared using information approved and signed off by CURE Pharmaceutical Holding Corp. management as approved for public dissemination. Although the information contained herein is believed to be reliable, LFC makes no warranties as to the accuracy of the description of any of the content herein and accepts no liability for how readers may choose to utilize it.

CURE Media Contact:
Ashley Ray
Olmstead Williams Communications
Aray@olmsteadwilliams.com
310-824-9000

Related posts
Wealth Minerals to Present at the LD Micro Main Event (XII)
December 6, 2019
CURE Pharmaceutical to Present at the 12th Annual LD Micro Main Event Investor Conference
December 5, 2019
CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors
November 19, 2019
CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension
November 14, 2019
Wealth Minerals Provides Corporate Update
November 12, 2019
Wealth Minerals Negotiates Land Access to Valsequillo Silver Project, Mexico
October 30, 2019
COMPANY & BLOG UPDATES
RECENT NEWS
  • Wealth Minerals to Present at the LD Micro Main Event (XII) December 6, 2019
  • CURE Pharmaceutical to Present at the 12th Annual LD Micro Main Event Investor Conference December 5, 2019
  • CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors November 19, 2019
  • CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension November 14, 2019
  • Wealth Minerals Provides Corporate Update November 12, 2019
CONTACT US
Phone: 415-389-4670
Fax: 415-389-4694
655 Redwood Highway #395
 Mill Valley, California 94941

Our privacy policy
COMPANY NEWS
  • Wealth Minerals to Present at the LD Micro Main Event (XII)
    December 6, 2019
  • CURE Pharmaceutical to Present at the 12th Annual LD Micro Main Event Investor Conference
    December 5, 2019
ABOUT LIVIAKIS
  • Testimonials
  • Press
  • Philanthropy
SITEMAP
  • About Liviakis
  • Services
  • Corporate Portfolio
  • Company News
  • Contact
Liviakis Financial Communications Inc.
©2015 Liviakis Financial | All Rights Reserved

Website Design: Hi 5 Studio | Video Production: Mav Media